NCT07616973Active, not recruitingPhase 3
Letrozole vs. Clomiphene Citrate Plus Tamoxifen for Ovulation Induction and Pregnancy Outcomes.
Letrozole Versus Clomiphene Citrate Plus Tamoxifen for Ovulation Induction and Pregnancy Outcomes in Infertile Women: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
Infertility is a common reproductive health problem. Ovulation induction is a key treatment for women with anovulatory infertility. Letrozole and clomiphene citrate are widely used medications for ovulation induction. Tamoxifen has also been used as an alternative or adjunct therapy. This randomized clinical trial aims to compare the effectiveness of letrozole versus clomiphene citrate combined with tamoxifen for ovulation induction and pregnancy outcomes in infertile women. The outcomes include ovulation rate, pregnancy rate, endometrial thickness, follicular development, Miscarriage rate, and Live birth rate. The study will be conducted at Al-Thawra Hospital in Sana'a, Yemen, under the supervision of Sana'a University. Keywords: Infertility, Ovulation Induction, Letrozole, Clomiphene Citrate, Tamoxifen
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- First submitted
- 20 May 2026
- Start date
- 1 May 2023
- Primary completion date
- 30 May 2026
- Lead sponsor
- Sana'a University
- NCT number
- NCT07616973
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 240
- From 1 May 2023 to the primary completion date, 30 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of ovarian drilling.
Other illness
- Active liver disease or renal disease.
- Documented pelvic diseases such as endometriosis, ovarian pathology, hydro- or pyosalpinx, or uterine fibroids.
- History of hypersensitivity reactions to study medications.
Other
- Spontaneous pregnancy.
- Women with hyperprolactinemia or thyroid dysfunction.
- Contraindications to letrozole, clomiphene citrate, or tamoxifen.
Who the study is looking for
- Women aged between 18 and 40 years.
- Patients with anovulatory polycystic ovaries.
- Presence of a normal uterus and patent fallopian tubes, as confirmed by hysterosalpingography (HSG).
- Husband's semen analysis within normal parameters.
- Normal serum prolactin and thyroid-stimulating hormone (TSH) levels.
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Thawra Hospital Coordinator of this site? Confirm its status | Sanaa | Yemen | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.